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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMTARGET I RCT (n¼227), TARGET I long stent cohort (n¼50), and TARGET II
registry (n¼730) was prospectively collected and analyzed in 1007 patients with de
novo native coronary lesions. All patients were exclusively treated with FIRE-
HAWK stent and the follow-up visits are at 1-, 6-, 12-month, and annually up to
5 years.
Results: 992 (98.5%) patients completed 2-year clinical follow-up. Between 1 and
2 years, 62% of patients discontinued DAPT and there were only 7 newly
occurred TLF events including 3 cardiac death, 1 TV-MI and 3 iTLR (table).
Importantly, no deﬁnite/probable stent thrombosis (ST) was observed in this cohort
5 days after implantation of FIREHAWK stents. Lesion length >¼30mm was
an independent predictor of TLF at 2 years (HR [95%CI]: 2.44 [1.32, 4.53],
p< 0.01).Table. Clinical Outcomes through 2 Years
1 Year 2 Years
(n¼1003) (n¼992)
Death, % (n) 0.8 (8) 1.4 (14)
Cardiac Death, % (n) 0.5 (5) 0.8 (8)
Myocardial Infarction, % (n) 2.8 (28) 3.1 (31)
Q Wave MI, % (n) 0.1 (1) 0.4 (4)
Non Q Wave MI, % (n) 2.7 (27) 2.7 (27)
Target Vessel MI, % (n) 2.8 (28) 2.9 (29)
Ischemia-Driven TLR, % (n) 0.9 (9) 1.2 (12)
Any Revascularization, % (n) 2.9 (29) 4.1 (41)
TLF, % (n) 3.9 (39) 4.6 (46)
PoCE (All-Cause Death / All Myocardial Infarction / Any
Revascularization), % (n)
4.1 (41) 7.8 (77)
Deﬁnite/Probable ST, % (n) 0.1 (1) 0.1 (1)Conclusions: The sustained 2-year clinical data indicates that FIREHAWK stent
could enable safety and efﬁcacy by a novel target eluting technology in mild to
moderate risk patients. However, large scale randomized trials (TARGET EU and III)
are needed to further conﬁrm its clinical beneﬁts in treating most complex patients/
lesions.TCT-606
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Background: In this randomized controlled study (RCT) we compare the clinical
efﬁcacy of the Orsiro Hybrid Drug Eluting Stent (Orsiro) with the Xience Prime
Everolimus Eluting Stent (Xience) at 2 years in the complete study population as well
as in the diabetic and small vessel subgroups, which are known to have a higher risk
for cardiac complications.
Methods: A total of N¼458 subjects (63.410.0SD 36-80 yrs) were enrolled in
the BIOFLOW-II study, registered at clinicaltrials.gov (NCT01356888). All sub-
jects were stratiﬁed for diabetes and then randomly assigned (2:1) to receive the
Orsiro or the Xience stent. Six patients were excluded from the intention to treat
population. The diabetic subgroup accounted for 28.3% N¼128 (Orsiro N¼84,
Xience N¼44) of all subjects. The small vessel cohort included all subjects with a
reference vessel diameter 2.75mm, accounting for 57.3% N¼259 (Orsiro N¼168,
Xience N¼91) of all subjects. Clinical follow up visits are performed at 1, 6, 12
months and annually for up to 5 years after the procedure. All angiographic im-
ages were analyzed by the core lab of R. Waksman, MD at MedStar HealthJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteResearch Institute, Washington DC, USA. All clinical events were adjudicated by
3 independent cardiologists (MD:s).
Results: All three study groups showed comparable populations in both randomi-
zation arms in terms of demographics, current risk factors, clinical history and lesion/
vessel characteristics. The clinical endpoint of Target Lesion Failure (TLF) for
Orsiro vs Xience at 12 month in the three analyzed populations were: All patients –
6.5% for the Orsiro vs 8.0% for the Xience (p 0.5832) Diabetic subgroup - 6.0%
for the Orsiro vs 4.5% for the Xience (p 0.7201) Small vessel subgroup – 7.4% for
the Orsiro vs 12.3% for the Xience (p 0.2065) No stent thrombosis (deﬁnitive,
probable or possible) occurred through 12 months. The clinical 2-year follow up data
is currently being analyzed. Results will be presented for the ﬁrst time during the
meeting.
Conclusions: In this RCT the clinical event rates of the Orsiro SES with a biode-
gradable polymer the clinical event rates were low and comparable to the Xience
Prime through 12 months in all three analyzed populations.
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Background: Bioresorbable polymer coatings are hoped to minimize persistent
inﬂammation associated with durable polymer usage as a drug carrier in drug-
eluting stents (DES). We examined the time course of para-strut inﬂammation (PI)
of 3 contemporary DES featuring abluminal bioresorbable polymer coating
(SYNERGYTM ¼SY) and durable polymer coating (XIENCE PRIME¼EES and
RESOLUTE INTEGRITY¼ZES) in the familial hypercholesterolemic swine (FHS)
model.
Methods: Stents (SE¼29, EES ¼29, ZES¼29 and OMEGA BMS¼29) were
implanted in 87 coronary arteries in 29 FHS. Para-strut inﬂammation (PI) was deﬁned
as contiguous regions of inﬂammation in contact with, or surrounding struts, and
extending into the neointima, media or adventitia and examined histologically at 30,
90 and 180 days.
Results: At 30 days, PI was higher in BMS compared to the 3 DES. By 90 days, PI
had markedly subsided in the BMS, but peaked in all 3 DES groups. At 180 days, PI
in the SY resolved to a minimal level comparable to BMS (p¼0.95), while the other 2
DES continued to show higher average PI scores than SY and BMS (EES vs. SY p<
0.0001 and ZES vs. SY p¼0.03).
Conclusions: In the setting of early atherosclerosis present in the FHS model at the
age used (12-25 months at implant), the peak PI in DES is delayed in comparison to
BMS and its resolution is slower. Polymer resorption and lower total mass of the
abluminally applied polymer coating in SY appear to accelerate the resolution of PI as
projected, adding to the evidence that FHS is capable of modeling clinically relevant
responses to endovascular interventions.TCT-608
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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comBackground: The new Inspiron (Scitech, Brazil) is a thin-strut (75 mm) cobalt-
chromium stent, abluminally coated with a thin (4.4 mg) PLA-PLGA polymeric layer,
eluted with low-dose sirolimus. The present study aims to evaluate the safety and
efﬁcacy proﬁle of the novel drug-eluting-stent in a very high-risk population treated in
a tertiary university hospital.
Methods: Up to May 2014, a total of 276 all-comers, without any speciﬁc anatomical
or clinical restriction, have been treated with the novel sirolimus-eluing stent im-
plantation and comprise this study population. Patients were maintained in dual an-
tiplatelet therapy for a minimum of 6 months and aspirin was prescribed indeﬁnitely
thereafter. Patients have been clinically followed-up at 1, 6 and 12 months post-
procedure.
Results: For the entire cohort, a total of 342 lesions were treated with 429
Inspiron stents. The included population had a very high risk proﬁle. Overall
53.6% were diabetics, 70.7% had multivessel disease, 39.5% were admitted with
acute coronary syndromes, heart failure was present in 16.7%, and 19.2% had
previous coronary surgery. Most lesions were type B2/C (79.8%), 31.7% were
bifurcations, and 17.6% were restenosis of a previously implanted stent. After a
mean follow-up of 136  101 days, the rate of target lesion-related death was
0.5%, myocardial infarction 4.9%, and target lesion revascularization 2.3%. There
was only one episode of (probable) stent thrombosis (total any thrombosis rate at
140 days was 0.4%).
Conclusions: The interim results of this real life registry demonstrate promising mid-
term safety and efﬁcacy results for the novel Inspiron sirolimus-eluing stent in the
treatment of highly complex patients.TCT-609
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Background: The current study aimed to compare the 1-year clinical outcomes after
implantation of the Cre8 (CID/Alvimedica, Saluggia, Italy) amphilimus, polymer-free
stent versus new generation everolimus eluting stents (EES) in a real-world patient
registry.
Methods: A total of 150 consecutive patients (197 lesions) treated with Cre8 between
January 2011 and August 2013 in 4 Italian centers were included. These were pro-
pensity matched for baseline characteristics with 150 patients (201 lesions) treated
with new generation EES during the same period. Primary outcome was one year
major adverse cardiovascular events (MACE), deﬁned as all-cause death, myocardial
infarction (MI) and target-vessel revascularization (TVR).
Results: Both groups had similar baseline characteristics including age (67.89.8
Cre8 vs. 66.99.7 EES years, p¼0.393), male gender (84% Cre8 vs. 86.7% EES,
p¼0.514) diabetes (28% Cre8 vs. 27.3% EES, p¼0.972), previous PCI (56% Cre8
vs. 58%EES, p¼0.726), previous CABG (22.0% Cre8 vs. 22.7% EES, p¼1.000)
and previous MI (33.3% Cre8 vs. 31.3% EES, p¼0.711). With regards to lesion
characteristics there was a higher prevalence of B2/C lesions in the EES group
(61.6% vs. 85.4%, P< 0.001) whereas the number of restenotic lesions was similar
(13.7% Cre8 vs. 11.0% EES, p¼0.413). Total stent length per patient
(35.425.4mm Cre8 vs. 36.626.3mm EES, p¼0.667) and SYNTAX score
(15.429.9 Cre8 vs. 15.2811.5 EES, p¼0.920) were similar in the two cohorts. At
one year, MACE rate (7.4% Cre8 vs. 10.2% EES, p¼0.261), all-cause mortality
(1.3% Cre8 vs. 1.4% EES, p¼0.823), TVR (5.2% Cre8, 8.8% EES. P¼0.169) and
target lesion revascularization-TLR (3% Cre8 vs. 7.4% EES, p¼0.108) were not
signiﬁcantly different between the two groups. There was a trend for reduced lesion
TLR at one year (3.5% Cre8, vs. 7.3% EES, p¼0.055) however this was lost after
adjustment for AHA lesion type. In patients with diabetes (Cre8 n¼42; EEE n¼41)
the 1-year TLR was 2.5% in the Cre8 group versus 14.6% in the EES group
(p¼0.056).
Conclusions: The Cre8 stent is safe and clinically effective, with similar 1-year
MACE, TVR and TLR rates as new generation EES in a “real-world” patient
registry.B178 JACC Vol 64/11/Suppl B j September 13–1Stents - Drug-eluting: Bioresorbable Scaffolds
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Background: The DESolve Novolimus Eluting Bioresorbable Coronary Scaffold
System (NEBCSS) is a drug-eluting bioresorbable scaffold combining a PLLA-based
scaffold coated with a biodegradable polylactide-based polymer and Novolimus, a
macrocyclic lactone mTOR inhibitor. The DESolve NX study is a prospective,
multicenter evaluation of the safety and efﬁcacy of the DESolve NEBCSS in patients
with single, de novo, native coronary artery lesions.
Methods: 126 patients receiving the study device were evaluated for multiple
clinical endpoints including: major adverse cardiac events-a composite endpoint
of cardiac death, target vessel MI, or clinically-indicated target lesion revascular-
ization, and stent thrombosis. Endpoints are assessed at 1, 6 and 12 months and
annually to 5 years. All patients underwent angiographic assessment at 6 months
with a subset of patients having IVUS and OCT at 6 months and MSCT at
12 months.
Results: Mean age at baseline was 62 years, 32% were females, and 21% diabetics.
Pre-procedure lesion length was 11.2 mm, RVD was 3.06 mm, and 18.3% of patients
had moderate-to-heavy calciﬁcation. Six-month QCA imaging demonstrated low
mean in-scaffold late lumen loss (0.20 mm), 18.3 %DS and an MLD of 2.45 mm.
Serial IVUS imaging (baseline and 6 months) demonstrated a signiﬁcant increase in
mean lumen (D 9.0%, p ¼ < 0.001) and scaffold areas (D 15.7%, p ¼ < 0.001) and
low % volume obstruction (5.05%); and serial OCT imaging demonstrated a signif-
icant increase in scaffold area (D 16.9 %, p ¼ < 0.001) and 98.78% endothelial
coverage of the scaffold at 6 months. Twelve-month MSCT results demonstrated that
lumen dimensions (21.8 %DS and 2.3mm MLD) were maintained from 6 to 12
months. Clinical events remained low (MACE ¼ 5.69% at 12 months) with no reports
of deﬁnite stent thrombosis.
Conclusions: DESolve demonstrated safety and efﬁcacy with low late lumen loss.
Serial imaging assessments indicated early vessel restoration at 6 months. At 12
months, the clinical event rate was low, and MSCT demonstrated good luminal
patency. Imaging endpoints and 2-year clinical results will be presented.TCT-611
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Background: Bioresorbable scaffold (BVS, Absorb, Abbott Vascular) are currently
used also for the treatment of acute coronary syndromes, but data on the outcome at
the level of the culprit plaque are still missing. Characteristics of a stable plaque
include a thick ﬁbrous cap and vasodilation in response to endothelium-dependent
vasodilators.
Methods: We describe the 12-months clinical, morphological and functional
outcome after BVS implantation for the treatment of culprit lesions in consecutive
patients with myocardial infarction. Vasomotion was assessed with infusions of
endothelium-dependent acetylcholine and endothelium-independent nitroglycerin.7, 2014 j TCT Abstracts/Stents - Drug-eluting: Bioresorbable Scaffolds
